By replacing short-acting ANP and BNP polypeptides, an anti-NPR1 antibody sustains NPR1 activation for longer heart failure treatment.
C3-carbon linked glutarimide Degronimers recruit cereblon and target proteins to drive selective in vivo degradation with therapeutic potential.
Specific FSHR-binding antibodies improve cancer and infertility treatment while using modular antibody regions to manage production complexity.
A defined THRB-CVD20 polypeptide fragment enables a polyclonal antibody to recognize and sort THRB-positive living cells.
QTY substitution replaces selected hydrophobic residues with hydrophilic ones to produce soluble membrane proteins while retaining ligand-binding activity.
Cre-LoxP system introduces autoantigen genes into animals, enabling stable antibody production without immune tolerance or leaky expression.
Magnetic clustering of paramagnetic nano-aAPCs expands antigen-specific T cells while preventing exhaustion from labor-intensive conventional methods.
A lyophilized detergent-protein composition preserves GPCR photochemical functionality during extended storage at minus 20 degrees Celsius.
A membrane protein stability assay uses fluorescent labels to detect aggregation via resonance energy transfer signals.
Truncated TSH receptor chimeras eliminate centrifugation steps and unspecific binding to improve detection accuracy.
A Renilla GFP-luciferase biosensor system tracks intracellular protein localization through Bioluminescence Resonance Energy Transfer signals.
Albumin-fused TSH receptor chimeras on paramagnetic particles resolve time and stability trade-offs in fully automatic autoantibody detection.
Antiandrogens bind tightly to androgen receptor Cys784 via covalent bonding, outcompeting natural steroids to prevent resistance.
Mrap2 gene knockout reduces maturation time by 50% while maintaining feed efficiency.
Monoclonal antibodies target the GnRH receptor to extend circulation half-life and reduce administration frequency while maintaining anti-cancer efficacy.
GPR101 inhibitors target the GPR101 receptor to control hormone levels in acromegaly, addressing incomplete disease management with somatostatin analogs.
A fusion polypeptide links channelrhodopsin to RyR2 via a defined linker, enabling precise optical activation of calcium channels.
KRAS-EF inhibitors reduce oncogenic KRAS levels, suppressing tumor growth and prolonging survival in preclinical models.
A computer-implemented method generates protein variants by identifying coupled allosteric sites and computing stability scores.
N-methylated MC5R antagonists resolve the delay in mood disorder treatment by delivering clinical improvement within days rather than weeks.